Joseph Amprey III

Form D signer

Joseph Amprey III

Chief Executive Officer at Zero Point Five Therapeutics

Form D signer

Capital raised by Zero Point Five Therapeutics

$4.3M+$4.3M latest round

1 Form D filing · first filed Apr 2025 · Baltimore, MD

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

Zero Point Five TherapeuticsBiotech · Baltimore, MDsince Apr 2025

Chief Executive Officer

Signatory on Zero Point Five Therapeutics's Form D filings · $4.3M raised across 1

Company filings

via EDGAR · Form D for Zero Point Five Therapeutics1

DateCompanyFormAmountRole on filing

Apr 2, 2025Zero Point Five TherapeuticsForm D+$4.3MChief Executive Officer

Form DApr 2, 2025 · Zero Point Five Therapeutics+$4.3Mas Chief Executive Officer

Overview

Last filing Apr 2, 2025

Joseph Amprey III is on file as Chief Executive Officer at Zero Point Five Therapeutics in Baltimore, MD. Zero Point Five Therapeutics has 1 Form D filing on record, $4.3M raised in total. Joseph Amprey III appears as a signatory on the company's filings.

Teammates

Zero Point Five Therapeutics · 1

Jodi JahicDirector

Products

Zero Point Five Therapeutics · 1

ZP5-9676Pharmaceuticals

ZP5-9676 is a drug candidate based on flubendazole and is currently in Phase 3 clinical trials, aimed at treating infections caused by soil-transmitted helminths including hookworm, roundworm, and whipworm.